Vimarsana
Biggest News Aggregation in the World

Thoracic Malignancies Programme News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thoracic Malignancies Programme. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thoracic Malignancies Programme Today - Breaking & Trending Today

Targeted Pulse: Social Determinants Link to Cervical Cancer, FDA News, and More - Vimarsana News

Targeted Pulse: Social Determinants Link to Cervical Cancer, FDA News, and More

This week's Targeted Pulse focuses on the latest in cervical cancer, the FDA ODAC's vote for cilta-cel, and more.

Expert Insights on the United States Chemotherapy Shortage - Vimarsana News

Expert Insights on the United States Chemotherapy Shortage

Oncology experts discuss the platinum chemotherapy shortage in the United States.

Experts Provide Key Perspectives on the US Cisplatin/Carboplatin Shortage - Vimarsana News

Experts Provide Key Perspectives on the US Cisplatin/Carboplatin Shortage

Experts from various institutions were interviewed by OncLive® at the 24th Annual International Lung Cancer Congress® about the ongoing platinum chemotherapy shortage in the United States.

Further Research May Delineate Immunotherapy Resistance Mechanisms in Lung Cancer - Vimarsana News

Further Research May Delineate Immunotherapy Resistance Mechanisms in Lung Cancer

Solange Peters, MD, PhD, discusses the successes and shortcomings of immunotherapy in patients with lung cancer; current challenges with defining resistance mechanisms to immunotherapy in this disease; and the potential applications of circulating tumor DNA monitoring in the early and metastatic disease settings.

Dr Peters on Understanding Mechanisms of Resistance to Immunotherapy in NSCLC - Vimarsana News

Dr Peters on Understanding Mechanisms of Resistance to Immunotherapy in NSCLC

Solange Peters, MD, PhD, discusses current understandings of mechanisms of resistance to immunotherapy in non–small cell lung cancer.